Patents Assigned to Eli Lilly & Company
  • Patent number: 5994371
    Abstract: The present invention relates to sulfonate and carbamate derivatives of 3-aroylbenzo[b]thiophenes, pharmaceutical formulations containing these compounds and methods of using such compounds for inhibiting the loss of bone, lowering serum cholesterol levels and therapeutically treating hormone dependent mammalian breast and uterine carcinoma.
    Type: Grant
    Filed: February 22, 1995
    Date of Patent: November 30, 1999
    Assignee: Eli Lilly and Company
    Inventors: Larry J. Black, Henry U. Bryant, George J. Cullinan
  • Patent number: 5990319
    Abstract: The present invention provides for the reaction of optionally substituted indole-3-acetamides with optionally substituted methyl indole-3-glyoxyl reagent to prepare potent PKC inhibitors. The reaction is a very efficient and robust macrocyclization methodology.
    Type: Grant
    Filed: August 22, 1997
    Date of Patent: November 23, 1999
    Assignee: Eli Lilly and Company
    Inventors: Margaret Mary Faul, Leonard Larry Winneroski, Jr.
  • Patent number: 5990308
    Abstract: This invention relates to a highly selective process for preparation of E-.omega.-phenyl-.omega.-(3-pyridyl)-.omega.-alkenoic acid derivatives bearing a carbamoyl substituted oxazolyl or oxazolinyl group on the phenyl ring which demonstrate utility for thromboxane receptor antagonism and/or thromboxane synthase inhibition, as well as to intermediates therefore.
    Type: Grant
    Filed: September 10, 1998
    Date of Patent: November 23, 1999
    Assignee: Eli Lilly and Company
    Inventors: Katrina Ann Nelson, Joseph John Nunes
  • Patent number: 5990129
    Abstract: The current invention provides methods for the up-regulation of trkA in a mammal, including humans, comprising the administration of an effective amount of a compound of formula I ##STR1## wherein R.sup.1 and R.sup.3 are, independently, --H, --CH.sub.3, --CO(C.sub.1 -C.sub.6 alkyl), or --COAr, where Ar is optionally substituted phenyl;R.sup.2 is selected from the group consisting of pyrrolidine, piperidine, and hexamethyleneimino; ora pharmaceutically acceptable salt or solvate thereof.In addition, the current invention provides method to increase the effect of NGF (Nerve Growth Factor), NGF-like activities or NGF agonists, whether such is from endogenous or exogenous sources.Further, the current invention provides methods for maintaining the homeostasis and health of the hippocampus, hypothalamus, and cortex, thus maintaining their biological functions.
    Type: Grant
    Filed: September 9, 1998
    Date of Patent: November 23, 1999
    Assignee: Eli Lilly and Company
    Inventors: Henry Uhlman Bryant, Robert Frank Santerre
  • Patent number: 5985865
    Abstract: A method of increasing gastroesophageal sphincter competence comprising administering to a human in need of treatment an effective amount of a compound having the formula ##STR1## wherein R.sup.1 and R.sup.3 are independently hydrogen, --CH.sub.3, ##STR2## wherein Ar is optionally substituted phenyl; R.sup.2 is selected from the group consisting of pyrrolidino, hexamethyleneimino, and piperidino; or a pharmaceutically acceptable salt or solvate thereof.
    Type: Grant
    Filed: April 20, 1998
    Date of Patent: November 16, 1999
    Assignee: Eli Lilly and Company
    Inventor: George Joseph Cullinan
  • Patent number: 5986114
    Abstract: The invention relates to benzopyranol derivatives which are intermediates in a process for stereoselectively forming N-substituted dihydro-2,3 benzodiazopines which are useful as AMPA receptor antagonists. The process includes an opening reduction step which sets the stereochemistry of the intermediates and the final compounds to the desired enantiomer. The reduction step may be carried out by an enzymatic reduction.
    Type: Grant
    Filed: March 2, 1999
    Date of Patent: November 16, 1999
    Assignee: Eli Lilly and Company
    Inventors: Benjamin A. Anderson, Marvin M. Hansen
  • Patent number: 5986106
    Abstract: A process for preparing 1H-indole-3-glyoxamides useful for inhibiting SPLA.sub.2 and novel intermediates useful in the preparation of such compounds.
    Type: Grant
    Filed: June 26, 1998
    Date of Patent: November 16, 1999
    Assignee: Eli Lilly and Company
    Inventors: Vien Van Khau, Michael John Martinelli, Joseph Matthew Pawlak
  • Patent number: 5986109
    Abstract: A compound of fomula XIV: ##STR1## wherein: R.sup.1a is --H or --OR.sup.7a in which R.sup.7a is a hydoxy protecting group;R.sup.2a is --H, halo, or OR.sup.8a in which R.sup.8a is a hydroxy protecting group; andR.sup.
    Type: Grant
    Filed: June 18, 1998
    Date of Patent: November 16, 1999
    Assignee: Eli Lilly and Company
    Inventors: Alan David Palkowitz, Kenneth Jeff Thrasher
  • Patent number: 5985322
    Abstract: An improved method for the treatment of central nervous system disorders comprises treating patients with an enteric fluoxetine formulation.
    Type: Grant
    Filed: March 10, 1999
    Date of Patent: November 16, 1999
    Assignee: Eli Lilly and Company
    Inventors: Neil R. Anderson, Roger F. Harrison, Daniel F. Lynch, Peter L. Oren
  • Patent number: 5985898
    Abstract: A method for alleviating the symptoms of post-menopausal syndrome comprising administering to a woman in need thereof an effective amount of a compound of formula I ##STR1## wherein R.sup.1a is --H or --OR.sup.7a in which R.sup.7a is --H or a hydroxy protecting group;R.sup.2a is --H, halo, or --OR.sup.8a in which R.sup.8a is --H or a hydroxy protecting group;R.sup.3 is 1-piperidinyl, 1-pyrrolidino, methyl-1-pyrrolidinyl, dimethyl-1-pyrrolidino, 4-morpholino, dimethylamino, diethylamino, diisopropylamino, or 1-hexamethyleneimino;n is 2 or 3; andZ is --O-- or --S--;or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: June 16, 1998
    Date of Patent: November 16, 1999
    Assignee: Eli Lilly and Company
    Inventor: Alan David Palkowitz
  • Patent number: 5981523
    Abstract: This invention provides thiomorpholinone compounds useful for treating multiple sclerosis of formula I wherein:R.sup.1 and R.sup.2 are each independently selected from C.sub.1 -C.sub.8 alkyl; C.sub.2 -C.sub.8 alkenyl; C.sub.2 -C.sub.8 alkynyl; C.sub.1 -C.sub.8 alkyloxy; C.sub.1 -C.sub.8 alkylthio; trifluoromethyl; C.sub.1 -C.sub.4 alkyl substituted with phenyl; phenyl; F; Cl; NO.sub.2 ; phenoxy; C.sub.1 -C.sub.4 alkyl substituted with phenoxy; thiophenyl; C.sub.1 -C.sub.4 alkylthiophenyl; --COOR.sup.7 ; --N(R.sup.7).sub.2 or --N(R.sup.7)SO.sub.2 R.sup.7 where each R.sup.7 is independently hydrogen or C.sub.1 -C.sub.6 alkyl;R.sup.3 is H or C.sub.1 -C.sub.4 alkyl;R.sup.4 and R.sup.5 are each individually H, or when taken together form a bond;R.sup.6 is H; C.sub.1 -C.sub.8 alkyl; C.sub.2 -C.sub.8 alkenyl; C.sub.2 -C.sub.8 alkynyl; --SO.sub.2 CH.sub.3 ; --(CH.sub.2).sub.n NR.sup.8 R.sup.9 ; --(CH.sub.2).sub.n CO.sub.2 R.sup.8 ; --(CH.sub.2).sub.n OR.sup.8 where n is an integer from 1 to 6, both inclusive, and R.
    Type: Grant
    Filed: August 14, 1997
    Date of Patent: November 9, 1999
    Assignee: Eli Lilly and Company
    Inventors: Jill A Panetta, Michael L Phillips
  • Patent number: 5981765
    Abstract: The present invention provides a compound of formula ##STR1## wherein R.sup.1a is --H or --OR.sup.7a in which R.sup.7a is a hydroxy protecting group;R.sup.2a is --H, halo, or --OR.sup.8a in which R.sup.8a is a hydroxy protecting group;R.sup.6 is --H or a hydroxy protecting group which can be selectively removed;R.sup.11 is non-existent or .dbd.O; andZ is --O-- or --S--;or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: June 18, 1998
    Date of Patent: November 9, 1999
    Assignee: Eli Lilly and Company
    Inventors: Alan David Palkowitz, Kenneth Jeff Thrasher
  • Patent number: 5981281
    Abstract: Provided herein is a method to produce knockout mutations at targeted sites in the genome of Streptococcus pneumoniae.
    Type: Grant
    Filed: December 8, 1997
    Date of Patent: November 9, 1999
    Assignee: Eli Lilly and Company
    Inventors: Richard Henry Baltz, Jo Ann Hoskins, Patricia Jean Solenberg, Patti Jean Treadway
  • Patent number: 5980938
    Abstract: The present invention provides methods of inhibiting PAI-1 using benzopyrans.
    Type: Grant
    Filed: June 25, 1997
    Date of Patent: November 9, 1999
    Assignee: Eli Lilly and Company
    Inventors: David Thompson Berg, George Joseph Cullinan, Brian William Grinnell, Mark Alan Richardson
  • Patent number: 5981570
    Abstract: The invention provides benzothiophene compounds, formulations, and methods of inhibiting bone loss or bone resorption, particularly osteoporosis, cardiovascular-related pathological conditions, including hyperlipidemia.
    Type: Grant
    Filed: September 22, 1997
    Date of Patent: November 9, 1999
    Assignee: Eli Lilly and Company
    Inventors: Henry Uhlman Bryant, George Joseph Cullinan, Jeffrey Alan Dodge
  • Patent number: 5977098
    Abstract: The invention provides a compound of formula I: ##STR1## or a pharmaceutically acceptable salt or solvate thereof; pharmaceutical formulations containing a compound of formula I, and methods of using a compound of formula I for the inhibition of bone loss or bone resorption and for treatment of cardiovascular-related pathological conditions.
    Type: Grant
    Filed: June 30, 1998
    Date of Patent: November 2, 1999
    Assignee: Eli Lilly and Company
    Inventor: Alan David Palkowitz
  • Patent number: 5977387
    Abstract: This invention provides processes for preparing cryptophycin compounds and novel intermediates which are useful in such processes.
    Type: Grant
    Filed: February 25, 1998
    Date of Patent: November 2, 1999
    Assignees: Eli Lilly and Company, Wayne State University, University of Hawaii
    Inventor: Vinod F Patel
  • Patent number: 5977121
    Abstract: There is disclosed a method of treating atherosclerosis, of preventing atherosclerotic lesions and plaque formation, of inhibiting atherogenesis, and of decreasing intracellular cholesterol accumulation through the administration of an effective amount of moxonodine, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: December 22, 1997
    Date of Patent: November 2, 1999
    Assignee: Eli Lilly and Company
    Inventor: Hans Jurgen Mest
  • Patent number: 5976866
    Abstract: This invention provides novel fungal strains altered in IPC synthase production, and a method for screening for inhibitors of fungal IPC synthase using whole cells.
    Type: Grant
    Filed: April 9, 1997
    Date of Patent: November 2, 1999
    Assignee: Eli Lilly and Company
    Inventors: Steven Alan Heidler, Jeffrey Alan Radding, Debra Ann Young
  • Patent number: 5977071
    Abstract: The present invention provides novel complexes consisting of certain GLP-1 molecules associated with a divalent metal cation that is capable of co-precipitating with a GLP-1 molecule. Pharmaceutical compositions and methods of using such complexes for enhancing the expression of insulin in B-type islet cells is claimed, as is a method for treating maturity onset diabetes mellitus in mammals, particularly humans.
    Type: Grant
    Filed: September 10, 1997
    Date of Patent: November 2, 1999
    Assignee: Eli Lilly and Company
    Inventors: John A. Galloway, James A. Hoffmann